

2024

Carbon Reduction Plan

Company: Celix Pharma

Reporting Period: 1/1/24-31/12/24

Report Completed On: 01/04/2025

In Partnerships with:



Document Version	V1
Amended date	01/04/25
Amended by	Surbhi Thakur

Table of Contents

Commitment to Achieving Net Zero.	3
Introduction	3
Project Background and Scope	4
Definitions:	5
Emissions Footprint Methodology	7
Organisation profile	7
Boundaries	8
Assumptions	8
Carbon Emissions Analysis (tCo2e)	9
Baseline data (tCo2e)	12
Carbon Analysis by Year (tCo2e)	13
Comments on Analysis	14
Carbon Offset Initiatives	16
Communication Plan	17
References	18
Declaration and Sign Off	19

Commitment to Achieving Net Zero.

Celix Pharma is committed to achieving Net Zero emissions by 2040 and is working with specialist consultancy [Beyond Procurement](#) to help facilitate this journey.

Climate change is the scientific term that describes the anthropogenic phenomenon that both human and natural systems will be influenced by the rise in global temperatures from the increasing release of greenhouse gases. In response, international, regional, national and local initiatives are being developed to mitigate the effects of climate change by reducing greenhouse gas emissions (GHGs) and thus keeping the rise of global temperatures to no more than 1.5°C above pre-industrial levels. According to the Paris Agreement, the global temperature is already 1°C above pre-industrial levels at its current state. To achieve the temperature goals laid out by the IPCC, all mitigations rely on quantification, monitoring, reporting, validation and verification of the GHG removal of CO₂ to a status of net zero by 2040.

Beyond Procurement is a specialist carbon and cost consultancy. They align their advice and reports not only to the IPCC goals, but the regulatory framework laid out by the ISO 14060 family of standards. These are described below:

- ISO 14064-1 : Details principles for managing and reporting upon organisation-level GHG inventories as well as including requirements for their removals. It also includes requirements and guidance on quality reporting, internal auditing and verification activities.
- ISO 14064-2 : Details the requirements for baseline scenarios when it comes to monitoring, quantifying and reporting of project emissions and removals. It focuses on GHG validating and verifying project activities which are designed to reduce the emissions.
- ISO 14064-3 : Details requirements for verifying GHG inventories and carbon footprint products. It describes the validation and verification procedures and evaluation of all project and product GHG statements.
- ISO 14065 : Defines requirements for bodies that validate/verify GHG statements. It can be used as a basis for accreditation and recognition as it is completely impartial and consistent across all verification bodies.
- ISO 14066 : Specifies competencies and requirements for validation and verification principles that all teams must be able to perform.
- ISO 14067 : Defines principles and requirements for quantification of carbon footprint of products (including goods, services and building/events). It is associated with life cycle stages of the product from beginning of resource extraction to end of life stages of the product.
- ISO/TS 14064-4 assists users in the application of ISO 14064-1, providing guidelines and examples for improving transparency in the quantification of emissions and their reporting.
- ISO 14068-1 : This document, published in 2023, is designed to outline carbon reporting and how a business can achieve carbon neutrality.


Project Background and Scope

The advice provided in this report has been adjusted for Celix Pharma. All information is backed by the ISO 14060 family of standards and is to the best of our knowledge complete.

The data in this report is reflective of the data received from our organisation and has been used to calculate a reporting year for our organisation in terms of all 3 scopes.

Beyond Procurement follows Greenhouse Gas Protocol regulations on leased offices. Should a lessee not have ownership or financial control over their office, emissions associated with fuel combustion fall under a scope 3 (upstream leased assets) analysis which is not covered in this report.

The remaining emissions may be offset through certified programs to achieve a 'Certification of Carbon Neutrality' for the particular year. The certification can only be awarded for the years offset and only once the organisation has removed and reduced its emissions to the greatest extent possible.



Definitions:

Reporting Period: Specific historical period (typically a year) selected to measure and report greenhouse gas emissions.


Baseline: The first reporting period that quantifies GHG emissions.

Greenhouse Gas emissions (GHG): Gaseous constituent of the atmosphere that absorbs and emits radiation at specific wavelengths within an infrared spectrum. The most common anthropogenic GHGs are carbon, methane, nitrous oxide, hydrofluorocarbons, nitrogen trifluoride, perfluorocarbons and sulphur hexafluoride. These GHGs can be reported as carbon dioxide equivalents using global warming potentials.

- **Carbon Dioxide equivalents:** Unit for expressing the radiative force of GHGs in relation to the most common gas, Carbon Dioxide. The equivalent is calculated by multiplying the mass of the GHG by its global warming potential.
- **Global warming potentials:** Is an index based on GHGs and measure the radiative force that follow a pulse emission of GHG. These GWP values are published by the Intergovernmental Panel on Climate Change (IPCC)
- **Carbon Footprint:** Sum of GHG emissions that is expressed in Carbon Dioxide Equivalents. They can either be done for an organisation (ISO 140065-1) or for individualised products (ISO 14067) and will be divided into 3 scopes that are defined below.
- **Scope 1:** direct emissions from activities owned or controlled by your organisation.
- **Scope 2:** energy indirect emissions are those released into the atmosphere that are associated with consumption of purchased electricity, heat, steam, and cooling. These indirect emissions are a consequence of your organisation's energy use but occur at sources you do not own or control.
- **Scope 3:** other indirect emissions are a consequence of your actions that occur at sources you do not own or control and are not classed as Scope 2 emissions. Examples of Scope 3 emissions are business travel by means not owned or controlled by your organisation, waste disposal, materials or fuels your organisation purchases. Deciding if emissions from a vehicle, office, or factory that you use are Scope 1 or Scope 3 may depend on how you define your operational boundaries. Scope 3 emissions can be from activities that are upstream or downstream of your organisation. More information on Scope 3 and other aspects of reporting can be found in the Greenhouse Gas Protocol Corporate Standard.
- **Offsetting:** Counterbalancing the carbon footprint. This is the final step in the process of calculations. Credits can be purchased (sometimes called retiring) in order to cancel out a certain value of carbon. Typically, this is one credit for 1 tonne of carbon equivalent.

Roadmap to net zero





Emissions Footprint Methodology

Beyond Procurement's methodology is fully detailed in Annex 3 - Beyond Procurement Methodology Document, which outlines the comprehensive approach they take to assist organisations in measuring and reducing their carbon emissions. This methodology aligns with ISO 14060 standards and the GHG Protocol's principles, ensuring accurate, transparent, and consistent reporting. It covers the definition of organisational and reporting boundaries, including all relevant GHG scopes, with a particular focus on detailed Scope 3 emissions analysis. Utilising up-to-date carbon factors and both location and market-based electricity accounting, They provide tailored support for data collection, assumption management, and results presentation. Notably, it employs proprietary technology to delve deep into supply chain emissions, enabling precise benchmarking and informed procurement decisions, ultimately driving tangible carbon reductions.

Organisation profile

Established in 2020, Celix Pharma is committed to bringing high quality, affordable, generic medicines into the UK for the health and well-being of patients, in line with its stated purpose "...for better health". By bridging gaps in the market across dosage forms, therapeutic areas and market channels, Celix intends to deliver substantial value to patients, payers, healthcare providers and its partners. Celix Pharma's business model is built around creating a commercially led, customer focused organization supported with strategic partnerships in R&D and manufacturing.

Celix Pharma is headquartered in the UK and is founded by professionals with considerable experience in the European pharmaceutical space across the entire value chain of a generic product, from research & development to commercialisation.

Celix Pharma operates within both primary and secondary care sectors and aims to provide its customers with a range of generics, branded generics and hospital specialty products.

Boundaries

Baseline Year: 01/01/23 – 31/12/23

Reporting period: 1/1/24-31/12/24

Geographic Boundaries: UK based. London Office.

Number of employees: 4

Details of serviced or leased offices: 1 serviced office.

Sinks: No GHG sinks identified.

GHG Protocol	Included/Excluded & reason	Data Source/ Quality
S1 - Company Facilities	Excluded	
S1 - Company Vehicles	Excluded	
S2 - Energy	Included	EPC
S3 - Category 1: Purchased Goods and Services	Excluded	
S3 - Category 2: Capital Goods	Excluded	
S3 - Category 3: Fuel and energy related activities	Included	EPC
S3 - Category 4: Upstream Transportation and Distribution	Excluded	
S3 - Category 5: Waste	Excluded	
S3 - Category 6: Business Travel	Included	Provided
S3 - Category 7: Employee Commuting	Excluded	
S3 - Category 8: Leased Assets	Excluded	
S3 - Category 9: Transportation & Distribution	Excluded	
S3 - Category 10: Processing of Sold Products	Excluded	
S3 - Category 11: Use of Sold Products	Excluded	
S3 - Category 12: End-of-Life of Sold Products	Excluded	
S3 - Category 13: Leased Assets	Excluded	
S3 - Category 14: Franchises	Excluded	
S3 - Category 15: Investments	Excluded	

Assumptions

Energy usage calculated from EPC and office space occupied.

Business travel taken from company records.

Carbon Emissions Analysis (tCo2e)


YEAR 2024 (Jan-Dec)

Total measured emissions	18.83
--------------------------	-------


Employees	4
Emission per employee	4.707355283

Emissions by Scope

Scope 1	0.00
Scope 2	0.59
Scope 3	18.24



Scope 1	0.00
Scope 2	0.59
Category 1: Purchased Goods and Services	0.00
Category 2: Capital Goods	0.00
Category 3: Fuel and energy related activities	0.05
Category 4: Upstream Transportation and Distribution	0.00
Category 5: Waste	0.00
Category 6: Business Travel	18.19
Category 7: Employee Commuting	0.00
Category 8: Leased Assets	0.00
Category 9: Transportation & Distribution	0.00
Category 10: Processing of Sold Products	0.00
Category 11: Use of Sold Products	0.00
Category 12: End-of-Life of Sold Products	0.00
Category 13: Leased Assets	0.00
Category 14: Franchises	0.00
Category 15: Investments	0.00



YEAR 2024 (Jan-Dec)						
Scope & Category	Quantity Units		EF kgCO ₂ e	Source	kgCO ₂ e	1es CO ₂ e
Scope 1						0.00
Scope 2						0.59
Electricity (EPC & sqm)	2835	kWh	0.207	BEIS 2024	586.85	0.59
Scope 3						
Category 1: Purchased Goods and Services						0.00
Category 2: Capital Goods						0.00
Category 3: Fuel and energy related activities						0.05
Electricity T&D losses	2835	kWh	0.018	BEIS 2024	50.79	0.05
Category 4: Upstream Transportation and Distribution						0.00
Category 5: Waste						0.00
Category 6: Business Travel						18.19
Flights - Economy	85301	kms	0.2001	BEIS 2024	17068.7	17.07
Train - International	1788	kms	0.0012	BEIS 2024	2.15	0.0
Train - Domestic	1140	kms	0.0408	BEIS 2024	46.51	0.05
Car	6437.38	kms	0.1669	BEIS 2024	1074.40	1.07
Category 7: Employee Commuting						0.00
Category 8: Leased Assets						0.00
Category 9: Transportation & Distribution						0.00
Category 10: Processing of Sold Products						0.00
Category 11: Use of Sold Products						0.00
Category 12: End-of-Life of Sold Products						0.00
Category 13: Leased Assets						0.00
Category 14: Franchises						0.00
Category 15: Investments						0.00

Baseline data (tCo2e)

BASELINE YEAR - 2023 (Jan-Dec)

Total measured emissions	27.60
---------------------------------	-------

Employees	2
Emission per employee	13.8




Emissions by Scope

Scope 1	0.00
Scope 2	0.00
Scope 3	27.60

Summary

Scope 1	0.00
Scope 2	0.00
Category 1: Purchased Goods and Services	0.00
Category 2: Capital Goods	0.00
Category 3: Fuel and energy related activities	0.00
Category 4: Upstream Transportation and Distribution	0.00
Category 5: Waste	0.00
Category 6: Business Travel	25.60
Category 7: Employee Commuting	2.00
Category 8: Leased Assets	0.00
Category 9: Transportation & Distribution	0.00
Category 10: Processing of Sold Products	0.00
Category 11: Use of Sold Products	0.00
Category 12: End-of-Life of Sold Products	0.00
Category 13: Leased Assets	0.00
Category 14: Franchises	0.00
Category 15: Investments	0.00

Carbon Analysis by Year (tCo2e)



Comments on Analysis

As the company continues to grow and increase its staff, the clear focus on reducing company travel has had a significant impact on carbon reduction. Focus will continue on detailed monitoring, while progressing into further GHG protocols.



Targets and Actions

Near Term (implement in the next 12 months)

Action: Measure purchased goods and services protocol and work closely with supply chain partners. Capture employee commuting data.

Medium term (implement in the next 24 months)

Action: Work with landlord to identify energy, water and water saving opportunities for services offices

Long term

Action: Implement cycle to work and EV salary sacrifice schemes as employee numbers grow.

Carbon Offset Initiatives

Carbon Offsetting may be embraced by Celix Pharma as an interim solution whilst we are actively working to reduce our emissions through proactive actions. Based upon our current measurement we may look to offsetting 20tCo2e through the following globally verified schemes.





Communication Plan

At Celix Pharma we recognise the importance of transparent and open communication regarding our carbon measurement and reduction efforts. This report is intended to provide our stakeholders, including investors, customers, employees and the wider community, with a clear understanding of our progress and commitment to sustainability.

We are committed to ongoing engagement and welcome feedback on this report. We will continue to refine our reporting practices to ensure they meet the evolving needs of our stakeholders and align with best-in-class standards.

This report will be made available on our company website. We will also communicate key findings through other communication channels such as press releases, social media and investor relations. We are open to dialogue and encourage stakeholders to contact us with any questions or comments.

We will review this report annually and update it to reflect our ongoing progress and new developments in carbon measurement and reduction. We will also actively participate in industry forums and collaborate with other organisations to drive collective action on climate change.

References

- ISO 14064-1:2018, Greenhouse gases — Part 1: Specification with guidance at the organization level for quantification and reporting of greenhouse gas emissions and removals.
- ISO 14064-2:2019, Greenhouse gases — Part 2: Specification with guidance at the project level for quantification, monitoring and reporting of greenhouse gas emission reductions or removal enhancements.
- ISO 14064-3:2019, Greenhouse gases — Part 3: Specification with guidance for the verification and validation of greenhouse gas statements.
- ISO 14067:2018, Greenhouse gases — Carbon footprint of products — Requirements and guidelines for quantification.
- IPCC (Intergovernmental Panel on Climate Change) reports.
- GHG Protocol (Greenhouse Gas Protocol) standards and guidance.
- Science Based Targets initiative (SBTi) resources.
- CDP (Carbon Disclosure Project) reporting guidelines.
- Global Reporting Initiative (GRI) standards.
- Task Force on Climate-related Financial Disclosures (TCFD) recommendations.
- Local or national governmental guides on carbon reporting.
- Peer reviewed scientific publications that are related to the **company's** specific industry.



Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/25 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported beyond the minimum compliance requirements of Streamlined Energy and Carbon Reporting (SECR), and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan, for the Financial Year ending on 31st December 2023, has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of Celix Pharma:

Directors Signature:



Directors Name: Shantreddy Soogareddy

Date: 1st April 2025



Completed in Partnership with:



www.beyondprocurement.co.uk

hello@beyondprocurement.co.uk